Summary

Market Insights

The Global EPA & DHA Market is built around a specialised ingredient supply chain that connects fisheries, seafood processors, marine oil refiners, biotechnology companies and manufacturers of nutritional products. Unlike general edible oils, EPA- and DHA-rich oils require controlled extraction, purification and concentration to achieve the fatty acid composition and quality demanded by their end users. The industry primarily obtains these ingredients from fish oil, while krill oil and other marine sources serve more specialised applications. Fish-processing by-products are also an important source of raw material: according to the Marine Ingredients Organisation (IFFO), they account for a substantial share of the raw materials used in fishmeal and fish oil production. This makes the availability of suitable fish stocks, seafood-processing activity and the efficient utilisation of processing by-products directly relevant to the supply of marine-derived omega-3 ingredients.

According to the research report "Global EPA and DHA Market Outlook, 2031," published by Bonafide Research, the Global EPA and DHA Market Outlook was valued at more than USD 2.68 Billion in 2025 and is anticipated to reach more than USD 4.10 Billion by 2031, expanding at a CAGR of 7.48% during 2026–2031. A defining feature of the industry is its exposure to fluctuations in marine raw material availability. Fish oil production is linked to fishing activity, catch quotas, species availability and environmental conditions, meaning that changes in fisheries can affect the volume and cost of raw materials available to ingredient manufacturers. FAO GLOBEFISH reporting on fishmeal and fish oil regularly tracks these supply conditions, including the effects of fishing restrictions and environmental events on production. In response, manufacturers are working with alternative sources and production methods, particularly oils derived from microalgae. Algal oil is commercially relevant because it can provide DHA without relying on fish as the immediate production source, making it suitable for applications where a non-fish-derived ingredient is preferred. Its use is also supported by regulatory assessment: the European Food Safety Authority has evaluated Schizochytrium-derived oil for proposed use in infant and follow-on formula, illustrating the role of regulatory review in the development of new EPA and DHA sources.

Demand for EPA and DHA comes from several distinct manufacturing industries, each with its own ingredient requirements. Dietary supplement producers use these oils in softgels, capsules and liquid formulations, while pharmaceutical manufacturers require carefully specified ingredients for specialised products. Infant formula manufacturers use DHA-containing oils as sources of long-chain omega-3 fatty acids, and food and beverage companies incorporate omega-3 ingredients into selected fortified products. Clinical nutrition and pet nutrition provide additional application areas, with ingredient selection depending on formulation requirements and the intended nutritional purpose. The Global Organization for EPA and DHA Omega-3s (GOED) identifies dietary supplements, pharmaceuticals, infant formula, food and beverages, pet nutrition, and clinical nutrition as distinct end-product applications within the industry. This diversity means that demand is not determined by consumer supplement purchasing alone; it is also shaped by product development and ingredient procurement decisions made by manufacturers across these industries.

Product quality is a central commercial consideration because EPA and DHA oils are sensitive to oxidation and must meet defined requirements for fatty acid content, purity and contaminant levels. The GOED Monograph, an industry quality standard, specifically addresses oxidative quality, environmental contaminants and the measurement of EPA and DHA. Its technical guidance also recognises that different oil types and chemical forms require appropriate analytical methods. These requirements influence the capabilities that ingredient suppliers must maintain, from raw material testing and refining to storage, packaging and finished-oil verification. For manufacturers supplying pharmaceutical, infant nutrition and premium supplement customers, reliable documentation and consistent ingredient specifications are therefore important parts of the commercial proposition, rather than simply additional quality-control measures.

Market Dynamics

Market Drivers
• Rising Demand from Dietary Supplements and Pet Nutrition Manufacturers: Demand from dietary supplement and pet nutrition manufacturers is becoming an important source of growth for the global EPA and DHA ingredient industry. In dietary supplements, manufacturers use EPA and DHA oils in softgels, capsules and liquid formulations, with product positioning increasingly focused on specific nutritional needs rather than general fish oil consumption. Pet food manufacturers are also incorporating omega-3 ingredients into premium formulations, particularly products positioned around skin and coat condition, joint support and overall animal wellness. This is creating demand from a different group of ingredient buyers, including pet food producers and specialised animal nutrition companies.
• Expansion of EPA and DHA Use in Aquaculture Feed Formulations: The increasing requirement for marine-derived nutrients in aquaculture feed is creating an additional commercial opportunity for EPA and DHA suppliers. Fish oil has traditionally been an important source of long-chain omega-3 fatty acids in aquafeed, particularly for farmed fish that require these nutrients for normal growth and nutritional quality. However, the availability of fish oil is constrained by the supply of suitable marine raw materials, while the expansion of aquaculture creates continued demand for reliable feed ingredients. This is encouraging feed manufacturers to evaluate alternative EPA and DHA sources, including microalgae-derived oils. The Centre for Feed Innovation's 2025 Algal Oil State of the Industry Report identifies algal oil as a commercially viable alternative in aquafeed and reports its transition from pilot applications to recurring use in commercial feed formulations.

Market Challenges
• Volatility in Fish Oil Availability and Raw Material Procurement Costs: Dependence on marine raw materials remains a significant challenge for EPA and DHA ingredient manufacturers. Fish oil production is closely connected to the availability of small pelagic fish, particularly Peruvian anchoveta, making the industry vulnerable to fishing restrictions, changing ocean conditions and fluctuations in catch volumes. The supply disruption during the 2023–2024 El Niño period demonstrated how a shortage of crude anchovy oil could increase procurement costs and affect the wider omega-3 supply chain.
• High Production Costs and Commercial Limitations of Alternative Sources: Although alternative sources such as algal oil can reduce dependence on wild-caught fish, their commercial expansion is constrained by production economics. Microalgae cultivation requires specialised facilities, controlled growing conditions, energy inputs and downstream extraction processes. These requirements can make algal EPA and DHA more expensive to produce than conventional fish oil, particularly when manufacturers need to supply large volumes at competitive prices.

Market Trends

• Transition Towards Higher-Concentration EPA and DHA Ingredients: Ingredient manufacturers are increasingly focusing on concentrated oils with higher total omega-3 content instead of relying exclusively on conventional refined fish oils. This shift allows manufacturers to deliver more EPA and DHA within a smaller quantity of oil and develop formulations with different fatty acid compositions. It is particularly relevant for supplement and pharmaceutical manufacturers, where ingredient concentration, product specifications and formulation requirements influence purchasing decisions.
• Diversification of Omega-3 Supply Through Algal and Other Alternative Oils: The industry is gradually broadening its raw material base to reduce exposure to fluctuations in conventional fish oil supply. Algal oil is receiving particular attention because it can provide DHA and EPA through controlled cultivation, without depending directly on wild-caught fish. Other approaches, including the use of marine processing by-products and additional oil sources, are also being explored to improve the resilience of ingredient supply.

Market Segments

DHA (Docosahexaenoic Acid) represents the largest product type segment in the global EPA & DHA market, primarily because of its extensive application in infant nutrition, dietary supplements and specialised nutritional products. Its recognised role in brain development, visual function and neurological health has established DHA as an important ingredient for manufacturers serving both early-life nutrition and adult wellness categories. The ingredient's presence across multiple consumer groups gives it a broader application base and strengthens its commercial importance compared with other omega-3 fatty acids.

DHA demand is closely connected to the growing use of specialised nutritional ingredients in products designed for different age groups and health requirements. Infant formula manufacturers incorporate DHA into formulations intended to provide nutritional support during early development, making product quality, purity and consistency important purchasing considerations. In the adult nutrition category, DHA is used in supplements positioned around cognitive wellness, eye health and general nutritional support. It is available in different formats, including softgel capsules, liquid oils, powders and concentrated ingredients, allowing manufacturers to develop products according to consumer preferences and formulation requirements. The supply landscape also supports its wider adoption, as DHA can be sourced from conventional marine oils as well as cultivated microalgae. Algal-derived DHA is particularly relevant for manufacturers targeting vegetarian consumers and applications where a fish-free ingredient is preferred. Ingredient suppliers invest in extraction, refining, concentration and stabilisation processes to achieve the required fatty acid composition while managing oxidation, taste and odour. These considerations are especially important for infant nutrition and premium supplement formulations, where manufacturers require dependable raw material specifications and consistent product performance. The combination of nutritional applications, sourcing alternatives and established use in specialised formulations contributes to DHA's leading position in the product type segment.

Dietary Supplements represent the largest application segment in the global EPA & DHA market, supported by the established use of omega-3 products as part of everyday nutritional and wellness routines. Growing consumer interest in cardiovascular health, cognitive function and general wellbeing has encouraged supplement manufacturers to include EPA and DHA in a wide range of formulations. Their availability through pharmacies, nutrition retailers, supermarkets and online platforms has also made omega-3 supplements accessible to consumers across different markets and purchasing categories.

The dietary supplements industry provides a broad commercial base for EPA and DHA ingredients because manufacturers can incorporate them into products with different concentrations, compositions and intended uses. Softgel capsules remain a recognised delivery format because they provide a convenient way to consume oil-based ingredients, while liquid formulations are used by consumers who prefer alternatives to capsules. Manufacturers also develop concentrated omega-3 products to deliver higher levels of EPA or DHA in a smaller serving size. The selection of raw materials depends on the product's positioning, with fish oil commonly used in conventional supplements and algal oil serving manufacturers targeting vegetarian and fish-free formulations. Ingredient suppliers must meet buyers' requirements for fatty acid composition, purity, oxidation control, contaminant management and shelf stability, as these characteristics influence both product quality and consumer acceptance. Formulation companies also pay attention to taste, odour and encapsulation performance because these factors can affect the overall experience of consuming omega-3 products. Distribution has expanded beyond traditional pharmacy channels, with specialist nutrition stores, direct-to-consumer websites and e-commerce marketplaces providing additional routes to consumers. Private-label supplement manufacturers and established nutrition brands further contribute to ingredient procurement through contract manufacturing and long-term supplier relationships. This combination of regular consumer purchasing, diverse product formats and broad distribution opportunities supports dietary supplements as the leading application segment.

Fish Oil accounts for the largest share of the global EPA & DHA market by source, owing to its established use as a commercial raw material for producing marine omega-3 ingredients. It provides a natural source of both EPA and DHA and benefits from a well-developed processing and distribution network connecting fishing companies, seafood processors, oil refiners and nutritional ingredient manufacturers. Its established industrial acceptance and suitability for multiple end-use applications make fish oil an important sourcing option for companies manufacturing supplements, pharmaceutical ingredients and fortified nutritional products.

The commercial availability of fish oil is supported by its connection with the wider seafood industry, where oils are obtained from selected oily fish and through the recovery of suitable materials generated during fish processing. Following extraction, the crude oil undergoes several processing stages to improve its quality and suitability for human consumption. Refining helps remove undesirable components, while purification and concentration technologies enable manufacturers to produce oils with different EPA and DHA profiles. Depending on the intended application, further processing may include molecular distillation and other separation techniques to achieve specific ingredient specifications. These processed oils are supplied to supplement manufacturers, pharmaceutical companies, infant nutrition producers and food ingredient businesses, each of which may require different fatty acid concentrations and quality parameters. Buyers generally assess fish oil based on its EPA and DHA composition, oxidation condition, contaminant levels, traceability and consistency between batches. Manufacturers must also maintain appropriate storage and handling conditions because exposure to oxygen, light and heat can affect oil stability and product quality. The established supplier network gives fish oil an advantage in terms of industrial familiarity, processing capabilities and availability of ingredients in different specifications. However, the source remains exposed to fluctuations in fishing activity, seasonal supply conditions, raw material procurement costs and marine resource management requirements.

Regional Insights

Asia-Pacific is projected to be the fastest-growing region in the global EPA & DHA market, driven by the expanding use of omega-3 ingredients across infant nutrition, dietary supplements, functional foods and specialised healthcare products. The region's growth is not limited to rising consumer demand; it is also supported by the development of local nutritional product manufacturing, increasing investment in health-focused food formulations and the growing commercial importance of marine and algae-derived ingredients. China, India, Japan, South Korea and Australia are important markets contributing to this regional expansion.

A distinctive feature of the Asia-Pacific market is the presence of different demand drivers across its major economies. In China, DHA has an established role in infant formula and maternal nutrition, creating opportunities for ingredient suppliers serving specialised food manufacturers. Japan represents a mature market where omega-3 ingredients are incorporated into supplements, functional foods and products targeting healthy ageing. In India, the opportunity is increasingly linked to the development of the organised dietary supplement industry, greater availability of branded nutritional products and the incorporation of health ingredients into everyday consumer offerings. South Korea and Australia also provide opportunities through premium nutrition products, health-conscious consumers and established food and supplement manufacturing industries. Alongside human nutrition, the region's aquaculture industry creates another commercial route for EPA and DHA ingredients, particularly where marine oils are used in specialised feed formulations. Regional seafood-processing activities also contribute to the availability of marine raw materials, although ingredient manufacturers continue to depend on international sourcing for certain concentrated oils and specialised inputs. At the same time, manufacturers are exploring algal-derived DHA to serve applications requiring fish-free ingredients and to diversify their sourcing options. These developments are encouraging suppliers to offer application-specific ingredients with suitable concentration levels, purity, stability and formulation characteristics.


Key Devlopments

• April 2026: dsm-firmenich Introduces Algal Oil for Pet Nutrition. dsm-firmenich announced the launch of Veramaris® O3 Max Pure, a microalgal oil designed to provide EPA and DHA in a ratio comparable to high-quality fish oil. Produced through closed-system microalgae fermentation, the ingredient offers pet food manufacturers an alternative source of omega-3 fatty acids with consistent composition and traceability.
• May 2026: EFSA Publishes Safety Assessment of Algal DHA Oil for Infant Formula. The European Food Safety Authority published a scientific opinion evaluating oil derived from Schizochytrium sp. A2 for use in infant and follow-on formula. The assessment examined its proposed use as a DHA-rich ingredient in infant nutrition and adult food supplements.
• July 2026: GOED Publishes Its Global EPA and DHA Ingredient Market Report. The Global Organization for EPA and DHA Omega-3s (GOED) released its 2026 Ingredient Market Report, examining raw material supply, ingredient volumes and developments across dietary supplements, pharmaceuticals, food and beverages, pet nutrition, infant formula and clinical nutrition.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• EPA & DHA Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendations

By Product Type
• Eicosapentaenoic Acid (EPA)
• Docosahexaenoic Acid (DHA)

By Application
• Dietary Supplements
• Infant Formula
• Pharmaceuticals
• Food & Beverages
• Clinical Nutrition & Medical Foods
• Pet Nutrition

By Source
• Fish Oil
• Algae Oil
• Krill Oil
• Other Marine Sources

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global EPA and DHA Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Product Type
6.5. Market Size and Forecast, By Application
6.6. Market Size and Forecast, By Source
7. North America EPA and DHA Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Product Type
7.4. Market Size and Forecast, By Application
7.5. Market Size and Forecast, By Source
7.6. United States EPA and DHA Market Outlook
7.6.1. Market Size by Value
7.6.2. Market Size and Forecast By Product Type
7.6.3. Market Size and Forecast By Application
7.6.4. Market Size and Forecast By Source
7.7. Canada EPA and DHA Market Outlook
7.7.1. Market Size by Value
7.7.2. Market Size and Forecast By Product Type
7.7.3. Market Size and Forecast By Application
7.7.4. Market Size and Forecast By Source
7.8. Mexico EPA and DHA Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast By Product Type
7.8.3. Market Size and Forecast By Application
7.8.4. Market Size and Forecast By Source
8. Europe EPA and DHA Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Product Type
8.4. Market Size and Forecast, By Application
8.5. Market Size and Forecast, By Source
8.6. Germany EPA and DHA Market Outlook
8.6.1. Market Size by Value
8.6.2. Market Size and Forecast By Product Type
8.6.3. Market Size and Forecast By Application
8.6.4. Market Size and Forecast By Source
8.7. United Kingdom (UK) EPA and DHA Market Outlook
8.7.1. Market Size by Value
8.7.2. Market Size and Forecast By Product Type
8.7.3. Market Size and Forecast By Application
8.7.4. Market Size and Forecast By Source
8.8. France EPA and DHA Market Outlook
8.8.1. Market Size by Value
8.8.2. Market Size and Forecast By Product Type
8.8.3. Market Size and Forecast By Application
8.8.4. Market Size and Forecast By Source
8.9. Italy EPA and DHA Market Outlook
8.9.1. Market Size by Value
8.9.2. Market Size and Forecast By Product Type
8.9.3. Market Size and Forecast By Application
8.9.4. Market Size and Forecast By Source
8.10. Spain EPA and DHA Market Outlook
8.10.1. Market Size by Value
8.10.2. Market Size and Forecast By Product Type
8.10.3. Market Size and Forecast By Application
8.10.4. Market Size and Forecast By Source
8.11. Russia EPA and DHA Market Outlook
8.11.1. Market Size by Value
8.11.2. Market Size and Forecast By Product Type
8.11.3. Market Size and Forecast By Application
8.11.4. Market Size and Forecast By Source
9. Asia-Pacific EPA and DHA Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Product Type
9.4. Market Size and Forecast, By Application
9.5. Market Size and Forecast, By Source
9.6. China EPA and DHA Market Outlook
9.6.1. Market Size by Value
9.6.2. Market Size and Forecast By Product Type
9.6.3. Market Size and Forecast By Application
9.6.4. Market Size and Forecast By Source
9.7. Japan EPA and DHA Market Outlook
9.7.1. Market Size by Value
9.7.2. Market Size and Forecast By Product Type
9.7.3. Market Size and Forecast By Application
9.7.4. Market Size and Forecast By Source
9.8. India EPA and DHA Market Outlook
9.8.1. Market Size by Value
9.8.2. Market Size and Forecast By Product Type
9.8.3. Market Size and Forecast By Application
9.8.4. Market Size and Forecast By Source
9.9. Australia EPA and DHA Market Outlook
9.9.1. Market Size by Value
9.9.2. Market Size and Forecast By Product Type
9.9.3. Market Size and Forecast By Application
9.9.4. Market Size and Forecast By Source
9.10. South Korea EPA and DHA Market Outlook
9.10.1. Market Size by Value
9.10.2. Market Size and Forecast By Product Type
9.10.3. Market Size and Forecast By Application
9.10.4. Market Size and Forecast By Source
10. South America EPA and DHA Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Product Type
10.4. Market Size and Forecast, By Application
10.5. Market Size and Forecast, By Source
10.6. Brazil EPA and DHA Market Outlook
10.6.1. Market Size by Value
10.6.2. Market Size and Forecast By Product Type
10.6.3. Market Size and Forecast By Application
10.6.4. Market Size and Forecast By Source
10.7. Argentina EPA and DHA Market Outlook
10.7.1. Market Size by Value
10.7.2. Market Size and Forecast By Product Type
10.7.3. Market Size and Forecast By Application
10.7.4. Market Size and Forecast By Source
10.8. Colombia EPA and DHA Market Outlook
10.8.1. Market Size by Value
10.8.2. Market Size and Forecast By Product Type
10.8.3. Market Size and Forecast By Application
10.8.4. Market Size and Forecast By Source
11. Middle East & Africa EPA and DHA Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Product Type
11.4. Market Size and Forecast, By Application
11.5. Market Size and Forecast, By Source
11.6. United Arab Emirates (UAE) EPA and DHA Market Outlook
11.6.1. Market Size by Value
11.6.2. Market Size and Forecast By Product Type
11.6.3. Market Size and Forecast By Application
11.6.4. Market Size and Forecast By Source
11.7. Saudi Arabia EPA and DHA Market Outlook
11.7.1. Market Size by Value
11.7.2. Market Size and Forecast By Product Type
11.7.3. Market Size and Forecast By Application
11.7.4. Market Size and Forecast By Source
11.8. South Africa EPA and DHA Market Outlook
11.8.1. Market Size by Value
11.8.2. Market Size and Forecast By Product Type
11.8.3. Market Size and Forecast By Application
11.8.4. Market Size and Forecast By Source
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2025
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. DSM-Firmenich AG
12.6.1.1. Company Snapshot
12.6.1.2. Company Overview
12.6.1.3. Financial Highlights
12.6.1.4. Geographic Insights
12.6.1.5. Business Segment & Performance
12.6.1.6. Product Portfolio
12.6.1.7. Key Executives
12.6.1.8. Strategic Moves & Developments
12.6.2. BASF SE
12.6.3. Croda International plc
12.6.4. KD Pharma Group
12.6.5. Corbion N.V.
12.6.6. Archer-Daniels-Midland Company
12.6.7. Omega Protein Corporation
12.6.8. Epax Norway AS
12.6.9. Nissui Corporation
12.6.10. Pharma Marine AS
12.6.11. Aker BioMarine
12.6.12. Bioriginal Food & Science Corp.
12.6.13. Bioriginal Food & Science Corp.
12.6.14. Connoils LLC
12.6.15. KinOmega Biopharm Inc.
12.6.16. Arjuna Natural Pvt. Ltd.
12.6.17. Clover Corporation Limited
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
15. Disclaimer

ページTOPに戻る

List of Tables/Graphs